公开(公告)号：US20090239839A1

公开(公告)日：2009-09-24

申请号：US12391520

申请日：2009-02-24

申请人： Fumio ITOH ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Hiroshi Mabuchi ,  Hiromi Yoshida ,  Hirokazu Matsumoto ,  Takeshi Wakabayashi

发明人： Fumio ITOH ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Hiroshi Mabuchi ,  Hiromi Yoshida ,  Hirokazu Matsumoto ,  Takeshi Wakabayashi

IPC分类号： A61K31/553 ,  A61P25/04

CPC分类号： C07D267/08

摘要： An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.

摘要翻译： 用于调节RFRP受体功能的试剂，其特征在于含有由式（I）表示的化合物[其中环A表示任选取代的芳环; 环B表示任选取代的苯环; X表示氧，S（O）n（n为0〜2的整数）或NR 3（R 3表示氢，任选取代的烃基或任意取代的杂环基）。 并且R 1和R 2各自表示氢，任选取代的烃基或任选取代的杂环基]或该化合物的盐。

公开(公告)号：US20070129348A1

公开(公告)日：2007-06-07

申请号：US10553273

申请日：2004-04-15

申请人： Fumio Itoh ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Hiroshi Mabuchi ,  Hiromi Yoshida ,  Hirokazu Matsumoto ,  Takeshi Wakabayashi

发明人： Fumio Itoh ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Hiroshi Mabuchi ,  Hiromi Yoshida ,  Hirokazu Matsumoto ,  Takeshi Wakabayashi

IPC分类号： A61K31/554 ,  A61K31/553 ,  A61K31/5513

CPC分类号： C07D267/08

摘要： An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.

摘要翻译： 用于调节RFRP受体功能的试剂，其特征在于含有由式（I）表示的化合物[其中环A表示任选取代的芳环; 环B表示任选取代的苯环; X表示氧，S（O）n N（n为0〜2的整数）或NR 3（R 3）表示氢， 任选取代的烃基或任选取代的杂环基）; 和R 1和R 2各自表示氢，任选取代的烃基或任选取代的杂环基]或该化合物的盐。

公开(公告)号：US20070117840A1

公开(公告)日：2007-05-24

申请号：US10549889

申请日：2004-03-16

申请人： Fumio Itoh ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Yoshihiro Banno ,  Hiromi Yoshida ,  Hirokazu Matsumoto

发明人： Fumio Itoh ,  Shuji Hinuma ,  Naoyuki Kanzaki ,  Yoshihiro Banno ,  Hiromi Yoshida ,  Hirokazu Matsumoto

IPC分类号： A61K31/4704

CPC分类号： A61K31/4704

摘要： A compound represented by the formula (I): wherein ring A represents an aromatic ring; X represents a bond, oxygen, NR4 (R4 represents hydrogen, a hydrocarbon group, or a heterocyclic group), or alkylene; R1 represents a hydrocarbon group, or a heterocyclic group; R2 represents —COYR5 (Y represents a bond, alkylene, oxygen, sulfur, or NR6 (R6 represents hydrogen, a hydrocarbon group, or a heterocyclic group), and R5 represents a hydrocarbon group, or a heterocyclic group), a hydrocarbon group, or a heterocyclic group; and R3 represents a hydrocarbon group, a heterocyclic group, optionally substituted hydroxy, optionally substituted amino, or —S(O)nR7 (R7 represents a hydrocarbon group, or a heterocyclic group, and n is 0 to 2), a salt of the compound, or a prodrug or either is useful as an agent for modulating the function of an RFRP receptor.

摘要翻译： 由式（I）表示的化合物：其中环A表示芳环; X表示键，氧，NR 4（R 4表示氢，烃基或杂环基）或亚烷基; R 1表示烃基或杂环基; R 2表示-COYR 5（Y表示键，亚烷基，氧，硫或NR 6（R 6） SUP>表示氢，烃基或杂环基），R 5表示烃基或杂环基），烃基或杂环基; 和R 3表示烃基，杂环基，任选取代的羟基，任选取代的氨基或-S（O）n R 7 （R 7表示烃基或杂环基，n为0〜2），化合物或前药的盐或其可用作调节其功能的试剂 RFRP受体。

公开(公告)号：US07045497B1

公开(公告)日：2006-05-16

申请号：US09868885

申请日：1999-12-22

申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

IPC分类号： A61K38/11 ,  A61K38/16 ,  C07K14/00 ,  C07H21/04

CPC分类号： A61K38/2257

摘要： The present invention relates to use of peptide to which G-protein coupled receptor protein recognizes as a ligand. Since the ligand polypeptide of the present invention has a stimulating action on oxytocin secretion, it is useful as a drug for ameliorating, preserving or treating various diseases related to oxytocin secretion such as uterine inertia, atonic hemorrhage, placental expulsion, subinvolution and the like.

摘要翻译： 本发明涉及G蛋白偶联受体蛋白识别为配体的肽的用途。 由于本发明的配体多肽对催产素分泌具有刺激作用，因此可用作改善，保存或治疗与催产素分泌相关的各种疾病如子宫惯性，失声性出血，胎盘排出，亚溶解等的药物。

公开(公告)号：US20050209151A1

公开(公告)日：2005-09-22

申请号：US11116727

申请日：2005-04-28

申请人： Chieko Kitada ,  Hirokazu Matsumoto ,  Shuji Hinuma

发明人： Chieko Kitada ,  Hirokazu Matsumoto ,  Shuji Hinuma

IPC分类号： A61K38/17 ,  A61P3/04 ,  A61P5/40 ,  A61K38/22

CPC分类号： A61K38/1709

摘要： The ligand polypeptides of the present invention have activity to regulate CRH secretion, and thus are useful as CRH secretion regulators for the relief, prevention or treatment of various diseases related to CRH secretion, such as hypoaldosteronism, hypocortisolemia, secondary and chronic adrenocorticism, Addison's disease (weakness, nausea, pigmentation, hypogonadism, alopecia, hypotension), adrenal dysfunction, and obesity, and also as analgesics.

摘要翻译： 本发明的配体多肽具有调节CRH分泌的活性，因此可用作CRH分泌调节剂用于缓解，预防或治疗与CRH分泌有关的各种疾病，例如醛糖醛酸降低症，低皮质醇血症，继发性和慢性肾上腺皮质激素，艾迪生病 （虚弱，恶心，色素沉着，性腺机能减退，脱发，低血压），肾上腺功能障碍和肥胖，以及止痛药。

公开(公告)号：US07598351B2

公开(公告)日：2009-10-06

申请号：US11004336

申请日：2004-12-03

申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

IPC分类号： C12P21/08

CPC分类号： G01N33/74 ,  C07K16/18 ,  C07K16/26 ,  G01N33/6854

摘要： The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.

摘要翻译： 本发明的抗-19P2配体单克隆抗体（特别是P2L-1Ca）具有非常高的结合能力，可中和19P2配体的花生四烯酸代谢物释放活性。 因此，它们可以用作垂体功能调节活性（例如催乳素分泌促进活性），中枢神经系统调节活性和胰腺功能的一些或其他异常引起的各种疾病的诊断，预防和/或治疗剂 19P2配体据称具有调节活性。

公开(公告)号：US07067268B1

公开(公告)日：2006-06-27

申请号：US09700643

申请日：1999-05-20

申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

IPC分类号： G01N33/53

CPC分类号： G01N33/74 ,  C07K16/18 ,  C07K16/26 ,  G01N33/6854

摘要： The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.

摘要翻译： 本发明的抗-19P2配体单克隆抗体（特别是P2L-1Ca）具有非常高的结合能力，可中和19P2配体的花生四烯酸代谢物释放活性。 因此，它们可以用作垂体功能调节活性（例如催乳素分泌促进活性），中枢神经系统调节活性和胰腺功能的一些或其他异常引起的各种疾病的诊断，预防和/或治疗剂 19P2配体据称具有调节活性。 使用本发明的单克隆抗体通过夹心技术（特别是使用单克隆抗体的夹心技术和识别19P2配体的中间部分的抗体）的免疫测定方法可以特异性且高灵敏度地测定19P2配体或其衍生物 。 该测定方法可用于阐明19P2配体或其衍生物的生理功能。

公开(公告)号：US20050158795A1

公开(公告)日：2005-07-21

申请号：US11004336

申请日：2004-12-03

申请人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

发明人： Hirokazu Matsumoto ,  Chieko Kitada ,  Shuji Hinuma

IPC分类号： C07K16/18 ,  C07K16/26 ,  C12P21/08 ,  G01N33/68 ,  G01N33/74 ,  G01N33/53

CPC分类号： G01N33/74 ,  C07K16/18 ,  C07K16/26 ,  G01N33/6854

摘要： The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.

摘要翻译： 本发明的抗-19P2配体单克隆抗体（特别是P2L-1Ca）具有非常高的结合能力，可中和19P2配体的花生四烯酸代谢物释放活性。 因此，它们可以用作垂体功能调节活性（例如催乳素分泌促进活性），中枢神经系统调节活性和胰腺功能的一些或其他异常引起的各种疾病的诊断，预防和/或治疗剂 19P2配体据称具有调节活性。 使用本发明的单克隆抗体通过夹心技术（特别是使用单克隆抗体的夹心技术和识别19P2配体的中间部分的抗体）的免疫测定方法可以特异性且高灵敏度地测定19P2配体或其衍生物 。 该测定方法可用于阐明19P2配体或其衍生物的生理功能。

公开(公告)号：US20120015868A1

公开(公告)日：2012-01-19

申请号：US13135230

申请日：2011-06-29

申请人： Chieko Kitada ,  Taiji Asami ,  Naoko Nishizawa ,  Tetsuya Ohtaki ,  Naoki Tarui ,  Hirokazu Matsumoto ,  Jiro Noguchi ,  Hisanori Matsui

发明人： Chieko Kitada ,  Taiji Asami ,  Naoko Nishizawa ,  Tetsuya Ohtaki ,  Naoki Tarui ,  Hirokazu Matsumoto ,  Jiro Noguchi ,  Hisanori Matsui

IPC分类号： A61K38/08 ,  A61P3/10 ,  A61P25/28 ,  A61P15/00 ,  A61P35/00 ,  A61P25/00 ,  A61P3/04 ,  A61P13/00 ,  C07K7/06 ,  A61P9/10

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.

摘要翻译： 本发明提供了一种转氨酶衍生物，其中包含转氨酶的氨基酸被替代的化学取代基修饰，导致转移衍生物，具有优异的血液稳定性和显示出癌转移抑制作用或癌生长抑制作用。

公开(公告)号：US07886181B2

公开(公告)日：2011-02-08

申请号：US12041059

申请日：2008-03-03

申请人： Hirokazu Matsumoto ,  Tsunehiko Baba ,  Shinji Hamada ,  Takashi Ichimura ,  Noriaki Takahashi

发明人： Hirokazu Matsumoto ,  Tsunehiko Baba ,  Shinji Hamada ,  Takashi Ichimura ,  Noriaki Takahashi

IPC分类号： G06F11/00

CPC分类号： G06F11/2025 ,  G06F11/0709 ,  G06F11/0793 ,  G06F11/1438 ,  G06F11/2041 ,  G06F11/2043

摘要： There is provided a method executed in a cluster system comprising a first computer and at least one second computer that stores the data transmitted from the first computer. The method comprising the steps of: judging whether the failure-occurred processing is restarted by the first computer or the failure-occurred processing is switched over by the second computer based on the system information; receiving the stored data from the second computer and re-executing the processing in which the failure has occurred by the first computer, in the case of which it is judged that the processing in which the failure has occurred is restarted by the first computer; and executing, by the second computer, the processing in which the failure has occurred, in the case of which it is judged that the processing in which the failure has occurred is switched over by the at least one second computer.

摘要翻译： 提供了一种在包括第一计算机和存储从第一计算机发送的数据的至少一个第二计算机的集群系统中执行的方法。 该方法包括以下步骤：基于系统信息，判断第一计算机重新启动故障发生处理或由第二计算机切换故障发生处理; 从所述第二计算机接收所述存储的数据并重新执行由所述第一计算机发生所述故障的处理，在判断已经发生所述故障的处理由所述第一计算机重新启动的情况下; 并且由所述第二计算机执行在所述至少一个第二计算机切换已经发生故障的处理的情况下发生故障的处理。